Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)
- Conditions
- IgG4 Related DiseaseIgG4-RD
- Interventions
- First Posted Date
- 2021-06-08
- Last Posted Date
- 2024-01-11
- Target Recruit Count
- 8
- Registration Number
- NCT04918147
- Locations
- ๐บ๐ธ
Massachusetts General Hospital, Boston, Massachusetts, United States
๐บ๐ธMayo Clinic: Pulmonary and Critical Care Medicine, Rochester, Minnesota, United States
๐บ๐ธEmory Healthcare, Atlanta, Georgia, United States
Evaluating the Safety and Immunogenicity of Stabilized CH505 TF chTrimer in Healthy, HIV-uninfected Adult Participants.
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2021-06-07
- Last Posted Date
- 2024-10-02
- Target Recruit Count
- 52
- Registration Number
- NCT04915768
- Locations
- ๐บ๐ธ
Vanderbilt Vaccine (VV) CRS, Nashville, Tennessee, United States
๐บ๐ธThe Hope Clinic of the Emory Vaccine Center CRS, Decatur, Georgia, United States
๐บ๐ธBrigham and Women's CRS, Boston, Massachusetts, United States
Selective CD28 Blockade in Renal Transplant Recipients
- Conditions
- Kidney TransplantationRenal Transplant Recipients
- Interventions
- Biological: LulizumabDrug: TacrolimusBiological: ThymoglobulinยฎDrug: MethylprednisoloneDrug: Mycophenolate MofetilDrug: Prednisone
- Locations
- ๐บ๐ธ
Emory University Hospital, Atlanta, Georgia, United States
First-in-Human Clinical Trial of a Mosaic Quadrivalent Influenza Vaccine Compared With a Licensed Inactivated Seasonal QIV, in Healthy Adults
- Conditions
- InfluenzaSeasonal Influenza
- Interventions
- Drug: VRC-FLUMOS0111-00-VP (FluMos-v1)Biological: FlucelvaxOther: VRC-GENADJ0110-AP-NV
- First Posted Date
- 2021-05-21
- Last Posted Date
- 2024-03-06
- Target Recruit Count
- 35
- Registration Number
- NCT04896086
- Locations
- ๐บ๐ธ
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines
- Conditions
- COVID-19
- Interventions
- Biological: mRNA-1273Biological: mRNA-1273.211Biological: SARS-CoV-2 rS/M1Biological: BNT162b2Biological: Ad26.COV2.SBiological: mRNA-1273.222
- First Posted Date
- 2021-05-17
- Last Posted Date
- 2025-01-03
- Target Recruit Count
- 867
- Registration Number
- NCT04889209
- Locations
- ๐บ๐ธ
University of Rochester Medical Center - Vaccine Research Unit, Rochester, New York, United States
๐บ๐ธCincinnati Children's Hospital Medical Center Vaccine Research Center, Cincinnati, Ohio, United States
๐บ๐ธUniversity of Pittsburgh - Medicine - Infectious Diseases, Pittsburgh, Pennsylvania, United States
Experimental Human Infection With Neisseria Gonorrhoeae (LptA Trial)
- Conditions
- Gonococcal Infection
- Interventions
- Drug: AzithromycinDrug: CeftriaxoneDrug: CiprofloxacinBiological: Neisseria gonorrhoeae strain FA1090 A26Biological: Neisseria gonorrhoeae strain FA7527
- First Posted Date
- 2021-05-03
- Last Posted Date
- 2021-12-02
- Target Recruit Count
- 16
- Registration Number
- NCT04870138
- Locations
- ๐บ๐ธ
University of North Carolina Health Care - Infectious Diseases, Chapel Hill, North Carolina, United States
Metabolic Profiling of Immune Responses in Immune-mediated Diseases
- Conditions
- Atopic DermatitisImmune-mediated DiseasesPrimary ImmunodeficiencyPsoriasis
- First Posted Date
- 2021-04-29
- Last Posted Date
- 2024-11-12
- Target Recruit Count
- 200
- Registration Number
- NCT04864886
- Locations
- ๐บ๐ธ
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
COVID-19 Vaccination and Outcomes in Individuals With and Without Immune Deficiencies and Dysregulations
- Conditions
- ImmunodeficienciesImmune Dysregulations
- First Posted Date
- 2021-04-21
- Last Posted Date
- 2024-10-01
- Target Recruit Count
- 308
- Registration Number
- NCT04852276
- Locations
- ๐บ๐ธ
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19
- Conditions
- Covid19
- Interventions
- Drug: Remdesivir PlaceboBiological: RemdesivirDrug: Aviptadil PlaceboBiological: AviptadilDrug: Corticosteroid
- First Posted Date
- 2021-04-14
- Last Posted Date
- 2023-05-03
- Target Recruit Count
- 473
- Registration Number
- NCT04843761
- Locations
- ๐บ๐ธ
VA Loma Linda Healthcare System (Site 074-017), 11201 Benton Street, Loma Linda, California, United States
๐บ๐ธRonald Reagan UCLA Medical Center (Site 203-002), 757 Westwood Plaza, Los Angeles, California, United States
๐บ๐ธCleveland Clinic Fairview Hosptial (Site 207-005), 18101 Lorain Ave., Cleveland, Ohio, United States
A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes.
- Conditions
- HIV InfectionsCMVCytomegalovirus
- Interventions
- First Posted Date
- 2021-04-09
- Last Posted Date
- 2024-01-11
- Target Recruit Count
- 44
- Registration Number
- NCT04840199
- Locations
- ๐บ๐ธ
Northwestern University CRS, Chicago, Illinois, United States
๐บ๐ธCase Clinical Research Site, Cleveland, Ohio, United States
๐บ๐ธUniversity of Pittsburgh CRS, Pittsburgh, Pennsylvania, United States